AI
CRDL

AXS Investments’s Cardiol Therapeutics CRDL Stock Holding History

AXS Investments’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-697,651
Closed -$579K – 326
2023
Q4 		$579K Sell
697,651
-75,884
-10% -$64.5K 0.14% 209
2023
Q3 		$706K Sell
773,535
-525,541
-40% -$502K 0.18% 181
2023
Q2 		$1.16M Sell
1,299,076
-428,751
-25% -$283K 0.31% 130
2023
Q1 		$844K Buy
+1,727,827
New +$1.02M 0.28% 135

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

AXS Investments's CRDL Position: Q1 2024 in Review

AXS Investments sold out of Cardiol Therapeutics (CRDL) in Q1 2024, closing a stake of 697,651 shares — an estimated $579K sold.

AXS Investments first reported a position in CRDL in Q1 2023 and held it in 4 quarters. The position peaked at $1.16M in Q2 2023. 35 funds tracked by Wall St. Rank hold CRDL as of Q1 2024.

  • AXS Investments reported no remaining Cardiol Therapeutics position as of Q1 2024 after selling out during the quarter.
  • AXS Investments sold 697,651 Cardiol Therapeutics shares in Q1 2024, an estimated $579K.
  • AXS Investments first reported a position in Cardiol Therapeutics in Q1 2023 and held it in 4 quarters.
  • AXS Investments's Cardiol Therapeutics position peaked at $1.16M in Q2 2023.
  • 35 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2024.

Based on AXS Investments's 13F filing for Q1 2024, filed 13 May 2024.